Search

Your search keyword '"Merino, L."' showing total 48 results
Start Over Author "Merino, L." Journal annals of oncology
48 results on '"Merino, L."'

2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

3. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., and O’Shaughnessy, J.

Published
2021
Full Text
View/download PDF

4. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Author

Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J.P., Taran, T., and Fasching, P.A.

Published
2021
Full Text
View/download PDF

5. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Author

Yardley, D.A., Coleman, R., Conte, P., Cortes, J., Brufsky, A., Shtivelband, M., Young, R., Bengala, C., Ali, H., Eakel, J., Schneeweiss, A., de la Cruz-Merino, L., Wilks, S., O’Shaughnessy, J., Glück, S., Li, H., Miller, J., Barton, D., and Harbeck, N.

Published
2018
Full Text
View/download PDF

6. 42TiP A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors

Author

Khushalani, N.I., primary, Shue, H., additional, Gedye, C., additional, Mazumder, A., additional, Sharma, S., additional, Eastgate, M., additional, Majem Tarruella, M., additional, Antonanzas Basa, M., additional, Montaudie, H., additional, Marais-Nieman, R., additional, de la Cruz Merino, L., additional, Clements, A., additional, Mortier, L., additional, Jameson, M., additional, Shojaei, F., additional, Ning, J., additional, Aiyer, L., additional, Gillings, M., additional, Kabbinavar, F., additional, and Ascierto, P., additional

Published
2022
Full Text
View/download PDF

7. 813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study

Author

Lewis, K., primary, Robert, C., additional, Ramella Munhoz, R., additional, Liszkay, G., additional, de la Cruz Merino, L., additional, Olah, J., additional, Queirolo, P., additional, Mackiewicz, J., additional, Li, H., additional, Zhu, Q., additional, Hertig, C., additional, Paranthaman, N., additional, McKenna, E.F., additional, Gutzmer, R., additional, McArthur, G., additional, and Ascierto, P.A., additional

Published
2022
Full Text
View/download PDF

8. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

Author

Piulats Rodriguez, J.M., primary, Piperno-Neumann, S., additional, Rutkowski, P., additional, Nathan, P., additional, Hassel, J.C., additional, Espinosa, E., additional, de la Cruz Merino, L., additional, Ochsenreither, S., additional, Shoushtari, A.N., additional, Orloff, M., additional, Salama, A.K.S., additional, Watkins, C., additional, Goodall, H., additional, and Baurain, J-F., additional

Published
2022
Full Text
View/download PDF

10. 1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716

Author

Luke, J.J., Ascierto, P.A., Khattak, M.A., Rutkowski, P., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Cruz Merino, L. de la, Chiarion Sileni, V., Kirkwood, J.M., Robert, C., Schadendorf, D., De Galitiis, F., Carlino, M.S., Odeleye-Ajakaye, A., Kalabis, M., Krepler, C., Eggermont, A.M.M., and Long, G.V.

Published
2024
Full Text
View/download PDF

11. LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

Author

Neven, P., primary, Fasching, P.A., additional, Chia, S., additional, Jerusalem, G., additional, De Laurentiis, M., additional, Im, S.-A., additional, Petrakova, K., additional, Bianchi, G.V., additional, Martin Jimenez, M., additional, Nusch, A., additional, Sonke, G.S., additional, de la Cruz Merino, L., additional, Beck, J.T., additional, Zarate, J.P., additional, Wang, Y., additional, Chakravartty, A., additional, Wang, C., additional, and Slamon, D., additional

Published
2022
Full Text
View/download PDF

12. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

13. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’

Author

Slamon, D.J., primary, Neven, P., additional, Chia, S., additional, Jerusalem, G., additional, De Laurentiis, M., additional, Im, S., additional, Petrakova, K., additional, Valeria Bianchi, G., additional, Martín, M., additional, Nusch, A., additional, Sonke, G.S., additional, De la Cruz-Merino, L., additional, Beck, J.T., additional, Ji, Y., additional, Wang, C., additional, Deore, U., additional, Chakravartty, A., additional, Zarate, J.P., additional, Taran, T., additional, and Fasching, P.A., additional

Published
2021
Full Text
View/download PDF

15. LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Author

Luke, J.J., primary, Rutkowski, P., additional, Queirolo, P., additional, Del Vecchio, M., additional, Mackiewicz, J., additional, Chiarion Sileni, V., additional, de la Cruz Merino, L., additional, Khattak, M.A., additional, Schadendorf, D., additional, Long, G.V., additional, Ascierto, P.A., additional, Mandala, M., additional, De Galitiis, F., additional, Sondak, V., additional, Scolyer, R.A., additional, Kirkwood, J.M., additional, Chen, K., additional, Ibrahim, N., additional, Ahsan, S., additional, and Eggermont, A.M.M., additional

Published
2021
Full Text
View/download PDF

16. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Miles, D., primary, Gligorov, J., additional, André, F., additional, Cameron, D., additional, Schneeweiss, A., additional, Barrios, C., additional, Xu, B., additional, Wardley, A., additional, Kaen, D., additional, Andrade, L., additional, Semiglazov, V., additional, Reinisch, M., additional, Patel, S., additional, Patre, M., additional, Morales, L., additional, Patel, S.L., additional, Kaul, M., additional, Barata, T., additional, O’Shaughnessy, J., additional, Zhang, Q., additional, Shao, Z., additional, Wang, X., additional, Geng, C., additional, Yan, X., additional, Tong, Z., additional, Shen, K., additional, Yin, Y., additional, Sun, T., additional, Yang, J., additional, Feng, J., additional, Yan, M., additional, Wang, Y., additional, Liu, Q., additional, Zhang, S., additional, De Laurentiis, M., additional, Santoro, A., additional, Guarneri, V., additional, Colleoni, M., additional, Natoli, C., additional, Cortesi, L., additional, Placido, S., additional, Gianni, L., additional, Ferrau, F., additional, Livi, L., additional, Zambelli, A., additional, Del Mastro, L., additional, Tonini, G., additional, Montemurro, F., additional, Bianchi, G., additional, Pedersini, R., additional, Prete, S., additional, Allegrini, G., additional, Naso, G., additional, Vici, P., additional, Loirat, D., additional, Mailliez, A., additional, Priou, F., additional, Tredan, O., additional, Dalenc, F., additional, Perrin, C., additional, Timar David, M., additional, Dohollou, N., additional, Teixeira, L., additional, Brocard, F., additional, Arnaud, A., additional, Delaloge, S., additional, Spano, J.-P., additional, Mansi, L., additional, Damian, F., additional, Pedrini, J., additional, Aleixo, S., additional, Hegg, R., additional, Junior, R., additional, Schmidt, M., additional, Wenzel, C., additional, Grischke, E.-M., additional, Just, M., additional, Harbeck, N., additional, Schumacher, C., additional, Peters, U., additional, Fischer, D., additional, Forstbauer, H., additional, Liersch, R., additional, Warner, E., additional, Bouganim, N., additional, Doyle, C., additional, Price Hiller, J., additional, Vandenberg, T., additional, Pavic, M., additional, Robinson, A., additional, Roldan Urgoiti, G., additional, Califaretti, N., additional, Alacacioglu, A., additional, Gumus, M., additional, Yalcin, B., additional, Cicin, I., additional, Kose, F., additional, Uygun, K., additional, Kaplan, M., additional, Cubukcu, E., additional, Harries, M., additional, Miles, D., additional, Doval, D., additional, Gupta, S., additional, Mohapatra, P., additional, Chatterjee, S., additional, Ghadyalpatil, N., additional, Singhal, M., additional, Nag, S., additional, Agarwal, A., additional, Wolf, I., additional, Gal Yam, E., additional, Yerushalmi, R., additional, Peretz, T., additional, Fried, G., additional, Ben Baruch, N., additional, Katz, D., additional, Hamilton, E., additional, Kayali, F., additional, Brufsky, A., additional, Telli, M., additional, Wright, G., additional, Oyola, R., additional, Rakowski, T., additional, Graff, S., additional, Tjulandin, S., additional, Aparicio, A., additional, Ruiz Borrego, M., additional, Merino, L., additional, Guerra Martinez, J., additional, Lopez, E., additional, Yamashita, T., additional, Ohtani, S., additional, Inoue, K., additional, Ito, Y., additional, Niikura, N., additional, Nakayama, T., additional, Sagara, Y., additional, Yanagita, Y., additional, Kamada, Y., additional, Kaneko, K., additional, Nervo, A., additional, Eniu, A., additional, Schenker, M., additional, Priester, P., additional, Melichar, B., additional, Zimovjanova, M., additional, Sormova, P., additional, Sufliarsky, J., additional, Kakalejcik, M., additional, Belbaraka, R., additional, Errihani, H., additional, Le Than, D., additional, Pham, D., additional, Aravantinos, G., additional, Papadimitriou, C., additional, Koumakis, G., additional, Papandreou, C., additional, Podolski, P., additional, and Tabane, K., additional

Published
2021
Full Text
View/download PDF

17. 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Author

Dang, C., primary, Ewer, M.S., additional, Delaloge, S., additional, Ferrero, J-M., additional, Colomer, R., additional, de la Cruz Merino, L., additional, Dadswell, K., additional, Verrill, M., additional, Eiger, D., additional, Sarkar, S., additional, de Haas, S., additional, Restuccia, E., additional, and Swain, S.M., additional

Published
2021
Full Text
View/download PDF

18. 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

Author

Tibau, A., primary, Martinez, M.T., additional, Ramos, M., additional, De la Cruz-Merino, L., additional, Santaballa, A., additional, Connor, M. O', additional, Martinez-Jañez, N., additional, Moreno, F., additional, Fernandez-Perez, I., additional, Virizuela, J.A., additional, Alarcón, J., additional, de la Haba-Rodríguez, J., additional, Sánchez-Rovira, P., additional, Albacar, C.R., additional, Bueno, C., additional, Kelly, C., additional, Casas, M., additional, Bezares, S., additional, Rosell, L., additional, and Albanell, J., additional

Published
2021
Full Text
View/download PDF

20. 1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study

Author

Lewis, K., primary, Robert, C., additional, Ascierto, P.A., additional, Munhoz, R., additional, Liszkay, G., additional, Merino, L. de la Cruz, additional, Olah, J., additional, Queirolo, P., additional, Mackiewicz, J., additional, Li, H., additional, Zhu, Q., additional, McKenna, E., additional, McNally, V., additional, Gutzmer, R., additional, and McArthur, G., additional

Published
2020
Full Text
View/download PDF

21. 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

Author

Weber, J., primary, Del Vecchio, M., additional, Mandala, M., additional, Gogas, H., additional, Fernandez, A.M. Arance, additional, Dalle, S., additional, Cowey, C.L., additional, Schenker, M., additional, Grob, J-J., additional, Sileni, V. Chiarion, additional, Márquez-Rodas, I., additional, Butler, M.O., additional, Maio, M., additional, Middleton, M., additional, Merino, L. de la Cruz, additional, Lobo, M., additional, de Pril, V., additional, Larkin, J., additional, and Ascierto, P.A., additional

Published
2020
Full Text
View/download PDF

22. 331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7

Author

De Laurentiis, M., primary, Merino, L. de la Cruz, additional, Hart, L., additional, Bardia, A., additional, Im, S-A., additional, Sohn, J., additional, Neven, P., additional, Martin, M., additional, Ji, Y., additional, Yang, S., additional, Hu, H., additional, Lteif, A., additional, and Tripathy, D., additional

Published
2020
Full Text
View/download PDF

23. LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)

Author

Albanell, J., primary, Martinez, M.T.M., additional, Ramos, M., additional, Connor, M.O.', additional, De la Cruz-Merino, L., additional, Santaballa Bertran, A., additional, Martínez-Jáñez, N., additional, Moreno, F., additional, Fernández Pérez, I., additional, Alarcon Company, J., additional, Virizuela Echaburu, J.A., additional, De la Haba Rodríguez, J., additional, Sánchez-Rovira, P., additional, González-Cortijo, L., additional, Margeli Vila, M., additional, Sánchez Munoz, A., additional, Garau Llinas, I., additional, Casas, M., additional, Bezares Montes, S., additional, and Rojo Todo, F., additional

Published
2020
Full Text
View/download PDF

24. LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

Author

Fernandez, A.M. Arance, primary, O'Day, S.J., additional, Merino, L. de la Cruz, additional, Petrella, T., additional, Jamal, R., additional, Ny, L., additional, Carneiro, A., additional, Berrocal, A., additional, Márquez-Rodas, I., additional, Spreafico, A., additional, Victoria Atkinson, V., additional, Costa Svedman, F., additional, Smith, A.D., additional, Chen, K., additional, Diede, S.J., additional, Krepler, C., additional, and Long, G.V., additional

Published
2020
Full Text
View/download PDF

26. Results from a Phase II Trial of Pembrolizumab (P) Plus Gemcitabine (GEM) in patients (PTS) with HER2-Negative Advanced Breast Cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study

Author

Merino, L. dela Cruz, primary, Cruz, J., additional, Alonso, J.L., additional, Garcia, V. Quiroga, additional, Anton, F. Moreno, additional, Andres, R., additional, Santiesteban, M., additional, Vazquez, M. Ramos, additional, Cortes, M. Gion, additional, Cortés, J., additional, Carrion, N. Palazon, additional, Lenza, I. Ceballos, additional, Soto, A., additional, Casas, M., additional, Benito, S., additional, Montes, S. Bezares, additional, and Holgado, E., additional

Published
2019
Full Text
View/download PDF

27. Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy

Author

Cortegana, C Jiménez, primary, Carrión, N Palazón, additional, Fernández, E Nogales, additional, García, M A Nieto, additional, Margalet, V Sánchez, additional, de la Gala, M D C Álamo, additional, de Ilárduya, M Suengas Martínez, additional, Burgos, E Montilla, additional, Fernández, I Araújo, additional, Carrasco, F Henao, additional, García-Sancho, A Martín, additional, Carnicero, F., additional, Herranz, E Rios, additional, de la Cruz Vicente, F., additional, Fernández, R., additional, Dominguez, A Rueda, additional, and de la Cruz Merino, L., additional

Published
2019
Full Text
View/download PDF

28. Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Author

Slamon, D.J., primary, Neven, P., additional, Chia, S., additional, Fasching, P.A., additional, De Laurentiis, M., additional, Im, S.-A., additional, Petrakova, K., additional, Bianchi, G.V., additional, Esteva, F.J., additional, Martin, M., additional, Nusch, A., additional, Sonke, G.S., additional, De la Cruz-Merino, L., additional, Beck, J.T., additional, Pivot, X., additional, Sondhi, M., additional, Wang, Y., additional, Chakravartty, A., additional, Rodriguez-Lorenc, K., additional, and Jerusalem, G., additional

Published
2019
Full Text
View/download PDF

30. Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast

Author

Quiroga, V., primary, Holgado, E., additional, Alonso, J.L., additional, Andres, R., additional, Moreno Anton, F., additional, Alamo De La Gala, M.D.C., additional, Henao, F., additional, Cirauqui Cirauqui, B., additional, Margeli, M., additional, Cortes Castan, J., additional, Gion Cortes, M., additional, Soto, A., additional, Benito, S., additional, Escudero, M.J., additional, Chiesa, M., additional, Caballero, R., additional, Bezares Montes, S., additional, Carrasco, E.M., additional, and De La Cruz Merino, L., additional

Published
2018
Full Text
View/download PDF

31. Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3

Author

Jerusalem, G., primary, Fasching, P.A., additional, Martín, M., additional, Pivot, X., additional, Petrakova, K., additional, Bianchi, G.V., additional, Nusch, A., additional, Sonke, G.S., additional, De La Cruz Merino, L., additional, Vagnon, E., additional, Alam, J., additional, Kong, O., additional, Chandiwana, D., additional, and De Laurentiis, M., additional

Published
2018
Full Text
View/download PDF

32. Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

Author

Piulats Rodriguez, J.M., primary, De La Cruz Merino, L., additional, Espinosa, E., additional, Alonso Carrión, L., additional, Martin Algarra, S., additional, López-Castro, R., additional, Curiel García, M.T., additional, Rodriguez Abreu, D., additional, Rullan Iriarte, A.J., additional, and Berrocal Jaime, A., additional

Published
2018
Full Text
View/download PDF

33. Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses

Author

Neven, P., primary, Petrakova, K., additional, Bianchi, G.V., additional, De La Cruz Merino, L., additional, Jerusalem, G., additional, Beck, J.T., additional, Sonke, G.S., additional, Chia, S., additional, Brucker, S., additional, Wang, Y., additional, He, W., additional, Rodriguez Lorenc, K., additional, Su, F., additional, and Im, S.-A., additional

Published
2018
Full Text
View/download PDF

35. 102P - Results from a Phase II Trial of Pembrolizumab (P) Plus Gemcitabine (GEM) in patients (PTS) with HER2-Negative Advanced Breast Cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study

Author

Merino, L. dela Cruz, Cruz, J., Alonso, J.L., Garcia, V. Quiroga, Anton, F. Moreno, Andres, R., Santiesteban, M., Vazquez, M. Ramos, Cortes, M. Gion, Cortés, J., Carrion, N. Palazon, Lenza, I. Ceballos, Soto, A., Casas, M., Benito, S., Montes, S. Bezares, and Holgado, E.

Published
2019
Full Text
View/download PDF

36. LBA7_PR - Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Author

Slamon, D.J., Neven, P., Chia, S., Fasching, P.A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G.V., Esteva, F.J., Martin, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., and Jerusalem, G.

Published
2019
Full Text
View/download PDF

37. 1267P - Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy

Author

Cortegana, C Jiménez, Carrión, N Palazón, Fernández, E Nogales, García, M A Nieto, Margalet, V Sánchez, de la Gala, M D C Álamo, de Ilárduya, M Suengas Martínez, Burgos, E Montilla, Fernández, I Araújo, Carrasco, F Henao, García-Sancho, A Martín, Carnicero, F., Herranz, E Rios, de la Cruz Vicente, F., Fernández, R., Dominguez, A Rueda, and de la Cruz Merino, L.

Published
2019
Full Text
View/download PDF

39. 88P - Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast

Author

Quiroga, V., Holgado, E., Alonso, J.L., Andres, R., Moreno Anton, F., Alamo De La Gala, M.D.C., Henao, F., Cirauqui Cirauqui, B., Margeli, M., Cortes Castan, J., Gion Cortes, M., Soto, A., Benito, S., Escudero, M.J., Chiesa, M., Caballero, R., Bezares Montes, S., Carrasco, E.M., and De La Cruz Merino, L.

Published
2018
Full Text
View/download PDF

45. Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)

Author

McArthur, G.A., primary, Ascierto, P.A., additional, Larkin, J., additional, Ribas, A., additional, Liszkay, G., additional, Maio, M., additional, Mandalà, M., additional, Demidov, L.V., additional, Stroyakovsky, D., additional, Thomas, L., additional, De La Cruz Merino, L., additional, Atkinson, V., additional, Dutriaux, C., additional, Garbe, C., additional, Chang, I., additional, Hack, S.P., additional, and Dréno, B., additional

Published
2014
Full Text
View/download PDF

46. LBA5_PR - Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)

Author

McArthur, G.A., Ascierto, P.A., Larkin, J., Ribas, A., Liszkay, G., Maio, M., Mandalà, M., Demidov, L.V., Stroyakovsky, D., Thomas, L., De La Cruz Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Chang, I., Hack, S.P., and Dréno, B.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results